Stockscreener 앱 받기
25.86
2.34%
-0.62
시간 외 거래:
25.86
전일 마감가:
$26.48
열려 있는:
$26.08
하루 거래량:
672.10K
Relative Volume:
0.92
시가총액:
$1.31B
수익:
$534.53M
순이익/손실:
$-11.45M
주가수익비율:
-107.26
EPS:
-0.2411
순현금흐름:
$48.28M
1주 성능:
-10.24%
1개월 성능:
-10.89%
6개월 성능:
-26.76%
1년 성능:
-23.94%
1일 변동 폭
$25.36
$26.14
1주일 범위
$25.36
$29.18
52주 변동 폭
$25.36
$43.18
Atricure Inc Stock (ATRC) Company Profile
명칭
Atricure Inc
전화
513-755-4100
주소
7555 INNOVATION WAY, MASON, OH
Compare ATRC vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATRC
Atricure Inc
|
25.86 | 1.34B | 534.53M | -11.45M | 48.28M | -0.2411 |
ISRG
Intuitive Surgical Inc
|
402.30 | 146.01B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
144.43 | 40.04B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
64.28 | 32.04B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
33.19 | 30.23B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
182.82 | 27.04B | 5.54B | 1.52B | 1.74B | 10.37 |
Atricure Inc Stock (ATRC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-18 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2026-02-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-12-17 | 재개 | JP Morgan | Overweight |
| 2024-04-23 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2023-10-23 | 개시 | JMP Securities | Mkt Outperform |
| 2023-09-29 | 개시 | UBS | Buy |
| 2021-08-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-12-18 | 재확인 | Needham | Buy |
| 2020-11-06 | 재확인 | Needham | Buy |
| 2020-04-07 | 개시 | Oppenheimer | Outperform |
| 2020-02-06 | 개시 | BTIG Research | Buy |
| 2020-01-24 | 재확인 | Needham | Buy |
| 2019-08-13 | 다운그레이드 | Northland Capital | Outperform → Market Perform |
| 2019-04-12 | 개시 | JP Morgan | Overweight |
| 2018-10-04 | 재확인 | Needham | Buy |
| 2018-08-02 | 재확인 | Needham | Buy |
| 2018-08-02 | 재확인 | Stifel | Buy |
| 2018-06-18 | 재확인 | Needham | Buy |
| 2018-04-27 | 재확인 | Needham | Buy |
| 2018-01-16 | 재확인 | Needham | Buy |
| 2017-11-02 | 재확인 | Needham | Buy |
| 2017-07-28 | 재확인 | Needham | Buy |
| 2017-05-30 | 재개 | Piper Jaffray | Overweight |
| 2016-06-30 | 재개 | JMP Securities | Mkt Outperform |
| 2015-10-28 | 재확인 | Needham | Buy |
| 2015-10-06 | 재확인 | Canaccord Genuity | Buy |
| 2015-10-06 | 재확인 | Needham | Buy |
모두보기
Atricure Inc 주식(ATRC)의 최신 뉴스
AtriCure stock hits 52-week low at 25.51 USD By Investing.com - Investing.com Australia
AtriCure stock hits 52-week low at 25.51 USD - Investing.com
Top 10 Small Cap Stocks With Huge Growth Potential - Insider Monkey
ATRC Stock Price, Quote & Chart | ATRICURE INC (NASDAQ:ATRC) - ChartMill
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference - Yahoo Finance
Insider Sell Alert: Karen Prange Sells 3,000 Shares of AtriCure Inc (ATRC) - GuruFocus
(ATRC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
AtriCure director Karen Prange sells $85,950 in company stock By Investing.com - Investing.com Canada
AtriCure director Karen Prange sells $85,950 in company stock - Investing.com
AtriCure (ATRC) director Prange sells 3,000 shares, keeps 26,373 - Stock Titan
Director Karen Prange granted 6,144 AtriCure (ATRC) shares - Stock Titan
AtriCure (ATRC) director Deborah Telman awarded 6,144 restricted shares - Stock Titan
AtriCure (ATRC) director Maggie Yuen receives 6,144-share restricted stock award - Stock Titan
Director Nachman Shlomo receives 6,144 AtriCure (ATRC) restricted shares - Stock Titan
Director Kristine Johnson receives 6,144-share grant at AtriCure (ATRC) - Stock Titan
AtriCure (ATRC) director Regina Groves receives 6,144-share restricted stock grant - Stock Titan
AtriCure (ATRC) director Sven Wehrwein receives 6,144-share restricted stock grant - Stock Titan
Director at AtriCure (ATRC) receives 6,144-share restricted stock grant - Stock Titan
[144] AtriCure, Inc. SEC Filing - Stock Titan
AtriCure Shareholders Approve Expanded Equity and Governance Plans - TipRanks
AtriCure (ATRC) stockholders back equity plan share increases and director slate - Stock Titan
AtriCure conference: New devices, EnCompass drive 2026 growth outlook - MSN
Insider Sell: Vinayak Doraiswamy Sells 5,000 Shares of AtriCure Inc (ATRC) - GuruFocus
AtriCure (ATRC) Chief Scientific Officer sells 5,000 shares at $28.13 - Stock Titan
AtriCure Inc Annual Shareholders Meeting Transcript - GuruFocus
Loss-Making AtriCure, Inc. (NASDAQ:ATRC) Set To Breakeven - 富途牛牛
ATRC (NASDAQ: ATRC) Form 144 shows 5,000-share sale and planned award disposals - Stock Titan
Wellington Management holds 3,382,555 ATRC shares (6.79%) — institutional stake - Stock Titan
AtriCure Inc (ATRC) Shares Surge 5.8% -- What GF Score of 79 Tel - GuruFocus
AtriCure stock (US04963C1099): Q1 revenue jumps 14% to $141M amid return to profit - AD HOC NEWS
AtriCure, Inc.Common Stock (NQ: ATRC - FinancialContent
AtriCure (ATRC) Is Down 5.1% After Q1 Return To Profitability And Higher Revenue Guidance – What's Changed - simplywall.st
TradingKey - TradingKey
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook - sharewise.com
ATRC: Innovation, clinical trials, and new launches drive growth and reinforce market leadership - TradingView
Transcript : AtriCure, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 10 - marketscreener.com
Responsive Playbooks and the ATRC Inflection - Stock Traders Daily
AtriCure, Inc. $ATRC Shares Purchased by Vanguard Group Inc. - MarketBeat
Number of shareholders of AtriCure, Inc. – NASDAQ:ATRC - TradingView
Number of shareholders of AtriCure, Inc. – DUS:A5I - TradingView
Assessing AtriCure (ATRC) Valuation After A Prolonged Share Price Decline - Yahoo Finance
AtriCure Inc stock hits 52-week low at 26.62 USD By Investing.com - Investing.com Australia
AtriCure, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ATRC) 2026-05-08 - Seeking Alpha
AtriCure Inc stock hits 52-week low at 26.62 USD - Investing.com
AtriCure : Investor Presentation Q1 2026 vF - marketscreener.com
AtriCure Q1 Loss Narrows, Revenue Increases; 2026 Guidance Maintained - Moomoo
Atricure Inc (ATRC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.52%
1.16%
자본화:
|
볼륨(24시간):